Show simple item record

dc.contributor.authorSperandio da Silva, G*
dc.contributor.authorFelix Mediano, M*
dc.contributor.authorHasslocher-Moreno, A*
dc.contributor.authorHolanda, M*
dc.contributor.authorSilvestre de Sousa, A*
dc.contributor.authorSangenis, L*
dc.contributor.authorBrasil, P*
dc.contributor.authorMejía, R*
dc.contributor.authorFux, C*
dc.contributor.authorCubides, J*
dc.contributor.authorSaraiva, R*
dc.contributor.authorBrum-Soares, L*
dc.date.accessioned2017-09-07T13:17:58Z
dc.date.available2017-09-07T13:17:58Z
dc.date.issued2017-06-22
dc.date.submitted2017-06-26
dc.identifier.citationBenznidazole Treatment Safety: The Médecins Sans Frontières Experience in a Large Cohort of Bolivian Patients with Chagas' Disease. 2017 J. Antimicrob. Chemother.en
dc.identifier.issn1460-2091
dc.identifier.pmid28645201
dc.identifier.doi10.1093/jac/dkx180
dc.identifier.urihttp://hdl.handle.net/10144/619010
dc.descriptionWe regret that this article is behind a paywall.en
dc.description.abstractUp to half of patients with Chagas' disease under benznidazole treatment present adverse drug reactions (ADRs) and up to one-third do not complete standard treatment.
dc.language.isoenen
dc.titleBenznidazole Treatment Safety: The Médecins Sans Frontières Experience in a Large Cohort of Bolivian Patients with Chagas' Diseaseen
dc.identifier.journalThe Journal of Antimicrobial Chemotherapyen
dc.internal.reviewer-noteNot OA.en
html.description.abstractUp to half of patients with Chagas' disease under benznidazole treatment present adverse drug reactions (ADRs) and up to one-third do not complete standard treatment.


This item appears in the following Collection(s)

Show simple item record